This same comparison also returned Arrdc3 as the 5th top hit (Fig. 1B), suggesting that loss of Arrdc3 confers a survival/growth advantage in Eμ-Myc lymphoma cells treated with the TP53/TRP53-activating drug nutlin-3a. This evidence concerns the gene TP53 and lymphoma.